Roberto Solari

Roberto is currently a Visiting Professor at the National Heart and Lung Institute at Imperial College London. Previously, he was Vice President and head of Biology in the respiratory therapy area at GlaxoSmithKline, UK. He spent 4 years as CEO of MRCT, the technology transfer arm of the MRC, where he helped the creation of spinout companies including Heptares. Before this he was an Advisor to Apax Partners, London and an Entrepreneur in Residence with Abingworth Management where he co-founded a number of companies including Astex Pharmaceuticals. Earlier he carried out research at the Universities of Oxford, UK, Lausanne, Switzerland and the University of Liverpool UK.

He is currently an Advisor to; Cincera Therapeutics, Ena Therapeutics and Wolf Biotherapeutics.

Roberto has a Bachelor of Science from the University of Nottingham and a PhD from the University of Nottingham.